. 2022 Aug 9;328(6):554–562. doi: 10.1001/jama.2022.11966

Table 1. Trial Characteristics.

Source^a	Dates of enrollment	No. of patients	Total No. of grafts^b	No. of SVGs	Experimental group			Control group			Treatment duration, mo	Type of graft imaging	Time to graft imaging, mo
Source^a	Dates of enrollment	No. of patients	Total No. of grafts^b	No. of SVGs	Treatment	No. of patients with SVGs	No. of SVGs	Treatment	No. ofpatients with SVGs	No. of SVGs	Treatment duration, mo	Type of graft imaging	Time to graft imaging, mo
TAP-CABG,⁸ 2016	2011-2014	70	167	76	Ticagrelor 90 mg 2/d + aspirin 81 mg 1/d	19	34	Placebo + aspirin 81 mg 1/d	23	42	3	CT angiography	3
DACAB,⁹ 2018	2014-2015	500	1146	712	Group 1: ticagrelor 90 mg 2/d + aspirin 100 mg 1/d	167	239	Aspirin 100 mg 1/d	166	242	12	CT or coronary angiography	12
					Group 2: ticagrelor 90 mg 2/d	166	231
TARGET,¹¹ 2022	2014-2019	250	688	373	Ticagrelor 90 mg 2/d	127	187	Aspirin 81 mg 2/d	123	186	12	CT angiography	12
POPular CABG,¹⁰ 2020	2015-2019	496	1078	507	Ticagrelor 90 mg 2/d + aspirin 80 mg or 100 mg 1/d	249	254	Placebo + aspirin 80 mg or 100 mg 1/d	247	253	12	CT angiography	12

Abbreviations: CT, computed tomography; SVG, saphenous vein graft.

^{^a}

See the Methods section for the full names of the studies.

^{^b}

Includes SVGs and arterial grafts (left and/or right internal thoracic artery, and radial artery).